Immunoglobulin Market Set for $25.15B Valuation by 2031 Amid Plasma Surge

The global immunoglobulin market is entering a phase of sustained expansion, with new projections placing its valuation at $25.15 billion by 2031. This trajectory is fundamentally underpinned by a strategic pivot in the pharmaceutical supply chain: the aggressive expansion of plasma collection capacity. For years, the industry was hamstrung by the "plasma bottleneck," where the availability of raw human plasma could not keep pace with the surging clinical demand for intravenous (IVIG) and subcutaneous (SCIG) therapies. As major players invest billions into automated collection technologies and new donor centers, the market is finally decoupling from these historical constraints.

The significance of this growth cannot be overstated in the context of rare disease management. Immunoglobulins are the standard of care for primary immunodeficiency (PID) and a range of autoimmune and neurological conditions, most notably chronic inflammatory demyelinating polyneuropathy (CIDP). Unlike synthetic drugs, immunoglobulins require a biological starting material that can take up to 12 months to process from donation to finished vial. The projected $25.15 billion figure suggests that the industry has successfully optimized this complex "vein-to-vial" cycle, ensuring that supply can meet a patient population that is being diagnosed earlier and treated more consistently.

“

The global immunoglobulin market is entering a phase of sustained expansion, with new projections placing its valuation at $25.15 billion by 2031.

From a competitive standpoint, the market remains dominated by a handful of global giants, including CSL Behring, Grifols, and Takeda. These companies have spent the last several years vertically integrating their operations. Grifols, for instance, has focused on expanding its footprint in the North American market, which remains the primary source of the world’s plasma supply due to its compensated donation model. Meanwhile, Takeda and CSL are increasingly focusing on the shift toward subcutaneous delivery. SCIG allows patients to self-administer their treatments at home, reducing the burden on hospital infusion centers and improving patient quality of life—a trend that is expected to capture a larger share of the $25.15 billion total.

Market analysts are also watching the impact of technological advancements in fractionation. New methods are allowing manufacturers to extract more protein from every liter of plasma, effectively increasing margins without requiring a proportional increase in donor volume. This efficiency, combined with the expansion of collection centers into emerging markets in Asia and Eastern Europe, provides a buffer against the rising costs of donor recruitment and retention. However, the industry remains sensitive to regulatory shifts regarding donor compensation and international trade of blood products, which could introduce volatility into the 2031 forecast.

Looking ahead, the focus will likely shift from pure volume to precision. As the $25.15 billion milestone approaches, the industry is exploring "next-generation" immunoglobulins and recombinant alternatives. While these are still in early stages, the robust cash flows generated by current IG sales are funding the R&D necessary to eventually supplement biological plasma with lab-grown proteins. For now, the expansion of physical collection infrastructure remains the most reliable indicator of market health. Investors and healthcare providers should monitor the rate of new center openings and the adoption of digital donor management platforms as lead indicators for this projected growth.